XBiotech to Attend and Present at the ASCO 2016 Gastrointestinal Cancers Symposium

January 21, 2016

Poster to Outline Details of U.S. Phase III Study of MABp1 in Patients With Advanced Colorectal Cancer (XCITE)

AUSTIN, Texas, Jan. 21, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, today announced that on January 23, 2016, Dr. Michael Stecher, the Company's Medical Director, will present as part of the Trials in Progress Poster Session at the American Society of Clinical Oncology (ASCO) 2016 Gastrointestinal Cancers Symposium in San Francisco, CA. The poster presentation, titled "Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer," is part of a special update for the gastrointestinal oncology community on XCITE, an ongoing FDA Fast Tracked, Pivotal Phase III study of XBiotech's cancer drug Xilonix™ for the treatment of metastatic colorectal cancer.

The poster will outline the details of XCITE, which is a global study of 600 patients with a primary endpoint of overall survival, and secondary endpoints of progression free survival, overall response rate, change in lean body mass, and quality of life. The study is powered to show a clinically meaningful improvement in overall survival, evaluated by log-rank test with a one-sided alpha of 0.025. Enrollment is currently underway, and results of the first interim analysis are expected in late 2016. The poster will also highlight positive results from a previous Phase I/II trial, which showed a survival benefit and symptomatic recovery in patients with advanced colorectal cancer.

Michael Stecher, M.D., the Company's Medical Director, stated, "Having successfully completed our European Phase III study using novel clinical endpoints developed with the EMA, I am gratified to have this opportunity to continue our positive momentum and highlight our global FDA trial for the GI cancer community."

The Gastrointestinal (GI) Cancers Symposium is a three-day specialized oncology event designed to provide scientific and educational content for members of the GI cancer care and research community.

About XBiotech
XBiotech is pioneering the discovery and development of targeted antibodies based on its True Human™ technology. The company's mission is to rethink the way antibody medicines are discovered and commercialized by advancing its robust pipeline of human antibodies for treating serious diseases such as cancer, inflammatory conditions and infectious diseases. XBiotech's lead product, Xilonix™, is a potential breakthrough antibody therapy that is currently the subject of two pivotal clinical studies for treating patients with advanced colorectal cancer. Xilonix specifically targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis, growth and spread of tumors, as well as mediate symptoms such as metabolic dysregulation, fatigue and anxiety associated with advanced cancer. XBiotech's True Human antibodies are cloned directly from individual donors who possess natural immunity against certain diseases. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Ashley Otero
XBiotech
aotero@xbiotech.com
512.386.2930

Tiberend Strategic Advisors, Inc.:

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com
212.375.2664

Janine McCargo (media)
jmccargo@tiberend.com
646.604.5150

XBiotech, Inc